Summary

The 7 major diabetic macular edema market reached a value of US$ 5.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 7.5 Billion by 2034, exhibiting a growth rate (CAGR) of 3.07% during 2024-2034.

The diabetic macular edema market has been comprehensively analyzed in IMARC's new report titled “Diabetic Macular Edema Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034”. Diabetic macular edema refers to a condition in which th small blood vessels in the retina are damaged as a result of diabetes, leading to swelling or accumulation of fluid in the macular, it often develops gradually and may not cause noticeable symptoms in the early stages. As the disease progresses, individuals might experience blurring of distortion of central vision, difficulty seeing fine details, or changes in color perception. In some cases, they may also notice blind spots or dark spots in their vision. In advanced stages, vision might become increasingly impaired, making it difficult to read, drive, or carry out other daily activities. The ailment is diagnosed through a comprehensive eye exam by an ophthalmologist. During the examination, the eye doctor will perform a visual acuity test to determine the clarity of vision and a dilated eye exam to assess the retina and optic nerve. Several specialized tests, such as optical coherence tomography (OCT) and fluorescein angiography (FA), are also utilized to evaluate the serverify as well as the extent of the ailment.

The increasing cases of high blood sugar levels in diabetic individuals, which damage the blood vessels in the retina, are primarily driving the diabetic macular edema market. In addition to this, the rising prevalence of several associated risk factors, including chronic inflammation, oxidative stress, accumulation of advanced glycation end products (AEGF) drugs, such as ranibizumab, aflibercept, bevacizumab, etc., for reducing fluid leakage in the macular and improving vision is acting as another growth-inducing factor. Additionally, the inflating utilization of vitrectomy, a surgical procedure in which the vitreous gel in the eye is removed and replaced with a clear saline solution, to treat cases where there is significant bleeding in the eye is further augmenting the market growth. Apart from this, the emerging popularity of subthreshold micropulse laser therapy over traditional laser therapy on account of its several associated benefits, including lower risk of damage to the retina, reduced discomfort during treatment, shorter recovery time, etc., is expected to drive the diabetic macular edema market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the diabetic macular edema market in the United States, EU5 (Germany, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for diabetic macular edema and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the diabetic macular edema market in any manner.


Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the diabetic macular edema market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the diabetic macular edema market
Reimbursement scenario in the market
In-market and pipeline drugs

Competitive Landscape:
This report also provides a detailed analysis of the current diabetic macular edema marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.


Key Questions Answered in this Report:
Market Insights

How has the diabetic macular edema market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the diabetic macular edema market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the diabetic macular edema market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of diabetic macular edema across the seven major markets?
What is the number of prevalent cases (2018-2034) of diabetic macular edema by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of diabetic macular edema by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with diabetic macular edema across the seven major markets?
What is the size of the diabetic macular edema patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of diabetic macular edema?
What will be the growth rate of patients across the seven major markets?

Diabetic Macular Edema: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for diabetic macular edema drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the diabetic macular edema market?
What are the key regulatory events related to the diabetic macular edema market?
What is the structure of clinical trial landscape by status related to the diabetic macular edema market?
What is the structure of clinical trial landscape by phase related to the diabetic macular edema market?
What is the structure of clinical trial landscape by route of administration related to the diabetic macular edema market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Diabetic Macular Edema - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034​)
4.4 Market Overview (2018-2023) and Forecast (2024-2034​)
4.5 Competitive Intelligence

5 Diabetic Macular Edema - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Diabetic Macular Edema - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034​)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034​)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034​)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034​)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034​)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034​)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034​)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034​)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)

8 Diabetic Macular Edema - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Diabetic Macular Edema - Unmet Needs

10 Diabetic Macular Edema - Key Endpoints of Treatment

11 Diabetic Macular Edema - Marketed Products
11.1 List of Diabetic Macular Edema Marketed Drugs Across the Top 7 Markets
11.1.1 Ozurdex (Dexamethasone ophthalmic) - AbbVie
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Iluvien (Fluocinolone acetonide) - Alimera/EyePoint Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Vabysmo (Faricimab) - Roche
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Lucentis (Ranibizumab) - Genentech/Novartis Ophthalmics
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Eylea (Aflibercept) - Bayer/Regeneron Pharmaceuticals/Sanofi
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 Diabetic Macular Edema - Pipeline Drugs
12.1 List of Diabetic Macular Edema Pipeline Drugs Across the Top 7 Markets
12.1.1 MYL1701P - Momenta Pharmaceuticals/Viatris
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 KSI 301 - Kodiak Sciences
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 APX3330 - Ocuphire Pharma
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 THR149 - Oxurion
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 EXN 407 - Exonate
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Diabetic Macular Edema - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Diabetic Macular Edema – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Diabetic Macular Edema - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Diabetic Macular Edema - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034​)
15.2.2 Diabetic Macular Edema - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034​)
15.3 Market Scenario - United States
15.3.1 Diabetic Macular Edema - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034​)
15.3.2 Diabetic Macular Edema - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034​)
15.3.3 Diabetic Macular Edema - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Diabetic Macular Edema - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034​)
15.4.2 Diabetic Macular Edema - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034​)
15.4.3 Diabetic Macular Edema - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Diabetic Macular Edema - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034​)
15.5.2 Diabetic Macular Edema - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034​)
15.5.3 Diabetic Macular Edema - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Diabetic Macular Edema - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034​)
15.6.2 Diabetic Macular Edema - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034​)
15.6.3 Diabetic Macular Edema - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Diabetic Macular Edema - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034​)
15.7.2 Diabetic Macular Edema - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034​)
15.7.3 Diabetic Macular Edema - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Diabetic Macular Edema - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034​)
15.8.2 Diabetic Macular Edema - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034​)
15.8.3 Diabetic Macular Edema - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Diabetic Macular Edema - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034​)
15.9.2 Diabetic Macular Edema - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034​)
15.9.3 Diabetic Macular Edema - Access and Reimbursement Overview

16 Diabetic Macular Edema - Recent Events and Inputs From Key Opinion Leaders

17 Diabetic Macular Edema Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Diabetic Macular Edema Market – Strategic Recommendations

19 Appendix